Table 1 Baseline characteristics of the patients
Acute HZ (≤ 30 days) | P value | ||
|---|---|---|---|
Contrast group (n = 57) | Stimulation group (n = 57) | ||
Age (years) | 67.0 ± 10.3 | 66.2 ± 11.7 | P = 0.72 |
Sex (M/F) | 25/32 | 16/41 | P = 0.12 |
Site of HZ infection | C: 14 | C: 13 | P = 0.52 |
T: 36 | T: 33 | ||
L: 7 | L: 11 | ||
HTN | 26 (46% [33, 58%]) | 21 (37% [26, 50%]) | P = 0.45 |
DM | 11 (19% [11, 31%]) | 16 (28% [18, 41%]) | P = 0.38 |
Asthma | 3 (5% [2, 14%]) | 1 (2% [0, 9%]) | P = 0.62 |
Hepatic disease | 5 (9% [4, 19%]) | 3 (5% [2, 14%]) | P = 0.72 |
Kidney disease | 2 (4% [1, 12%]) | 3 (5% [2, 14%]) | P = 1.0 |
Avg. amount of ropivacaine in the infusion device (ml) | 37.7 ± 3.8 | 37.5 ± 4.0 | P = 0.79 |
Baseline pain scorea | 8 (7–8) | 8 (7–8) | P = 0.22 |